$SCTX

ARK ETFs sold 670,746 shares of Personalised (PSNL) for $10.7M, bought 254,668 shares of Freenome (FRNM) for $3.1M, sold 59,477 shares of CareDx (CDNA) for $4M, and bought 29,416 shares of Scribe Therapeutics (SCTX) for $609K. These trades indicate ARK's strategic portfolio adjustments.

ARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).

ARK Genomic Revolution ETF (ARKG) managed by Cathie Wood bought shares of Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Beam Therapeutics (BEAM), and Scribe Therapeutics (SCTX), while selling 10x Genomics (TXG). Other ETFs like GNOM, PBE, FBT, and XBI also hold these biotech companies, offering varied exposure to genomics and biotechnology sectors.

ARK Invest increased stakes in Ionis Pharmaceuticals (IONS), Veracyte (VCYT), Scribe Therapeutics (SCTX), and Beam Therapeutics (BEAM), while reducing exposure to 10x Genomics (TXG). The ETF bought shares worth millions in each biotech firm, with IONS, SCTX, and BEAM seeing pre-market gains, while VCYT declined. ARK also invested $37 million in Meta Platforms (META) across three ETFs, following a surge in Meta's shares.

Scribe Therapeutics, Inc. (SCTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to d

Analysts upgraded Deere (DE) to Outperform with a $800 target, citing strong North American demand. Abercrombie & Fitch (ANF) was upgraded to Buy with a $162 target after Q2 earnings beat. Agco (AGCO) upgraded to Outperform with a $150 target, expecting 2027 volume recovery. Kaiser Aluminum (KALU) upgraded to Buy with a $184 target. Stag Industrial (STAG) upgraded to Outperform. PG&E (PCG) downgraded by Wells Fargo and BMO. Mizuho downgraded PG&E, Sempra Energy (SRE), and Edison International (E

Wall Street analysts made several calls: Baird upgraded AGCO to $150 and Deere to $800, while Mizuho downgraded Edison International and Sempra Energy. Evercore ISI initiated Lumentum at Outperform with a $1,100 target, and Roth Capital started Ticketplus at Buy with a $14 target. Markets closed lower Friday due to Fed rate-hike concerns, with Treasury yields rising and major indices down.

Analysts initiated coverage of Scribe Therapeutics (SCTX), a gene-based therapeutics company that IPOed on Nasdaq in late July. Wells Fargo rated it overweight and set a $60 price target, implying 183% upside. Leerink set an outperform with a $37 target, and Guggenheim set a buy with a $50 target. Coverage cites its PCSK9 epigenetic silencing approach and expected first-in-human data in 1H 2027.

Analyst actions: DA Davidson upgraded Duolingo (DUOL) to Buy, PT $160 (from $130). Citi upgraded Bath & Body Works (BBWI) to Buy, PT $25. KeyBanc upgraded Acadia Realty Trust (AKR) to Overweight, PT $25. Mizuho downgraded Norwegian Cruise Line (NCLH) to Neutral, PT $17 (from $22). Multiple other upgrades/downgrades and initiations were issued across retail, real estate, telecom, and healthcare.

Eli Lilly and Company disclosed a 7.36% stake in Scribe Therapeutics, Inc. common stock. The position combines shares from a July 10, 2026 conversion of an 8% convertible note and 333,333 shares bought in Scribe’s July 23, 2026 IPO, according to a Schedule 13D filed on Jul. 30, 2026. The move links a major pharmaceutical company to Scribe following its IPO and signals potential engagement.